Welcome to the Oncotype DX® Website
Select your Country and Language

Oncotype DX® is Genomic Health’s flagship line of gene expression tests that have been used to guide treatment decisions for more than half a million cancer patients worldwide.


Healthcare Professional

Managed Care

Breast Recurrence and DCIS

The Oncotype DX breast cancer assays can help physicians and patients decide on the best course of treatment. For invasive breast cancer, the Oncotype DX Breast Recurrence Score predicts chemotherapy benefit and the likelihood of distant breast cancer recurrence. The Oncotype DX Breast DCIS Score predicts the risk of local recurrence. Even when traditional measures seem conclusive, Oncotype DX can lead to a different approach.

Oncotype DX Colon Recurrence Score

The Oncotype DX Colon Recurrence Score quantifies recurrence risk in stage II and stage III colon cancer, beyond traditional qualitative measures. This enables an individualized approach to treatment planning. The Oncotype DX test measures a group of cancer genes in the tumor, providing a quantitative Recurrence Score® result beyond traditional measures so physicians and patients can have a more complete discussion of recurrence risk.

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score harnesses the power of genomics to provide a more precise and accurate assessment of risk based on individual tumor biology. Using a minimal tissue sample from a needle biopsy, the test builds on traditional clinical pathologic factors to provide additional, clinically relevant insight into the underlying prostate tumor biology, enabling physicians and their patients to make treatment decisions with greater confidence.